Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

BACKGROUND: Treating psoriasis in patients with concomitant hepatitis C virus (HCV)
infection presents a special challenge. Not only is psoriasis exacerbated by interferon …

Background Patients with psoriasis who are treated with systemic and biologic therapies
may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that …

Background Tumor necrosis factor inhibitory agents are currently considered to be
contraindicated in psoriatic patients with hepatitis B. Objective We aim to provide guidance …

Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

Introduction: Biologics are highly effective, important treatment options for moderate-to-
severe psoriasis. Biologics are well tolerated and have few side effects. However, the use of …

Biological therapies used in psoriasis treatment pose a risk of reactivation of hepatitis B virus
(HBV) infection. This risk occurs not only in patients with HB surface antigen (HBsAg)(+) but …

Abstract Treatment of severe psoriasis in HCV positive patients is challenging, because
several psoriasis medications have a toxic effect on the liver, and interferon alpha, used to …